Bladder control problems in men (urinary incontinence). National Institute of Diabetes and Digestive and Kidney Diseases website. Available at: https://www.niddk.nih.gov/health-information/urologic-diseases/bladder-control-problems-men. Updated November 2015. Accessed December 19, 2017.
Occhino J, Siegel S. Sacral nerve modulation in overactive bladder. Curr Urol Rep. 2010;11(5):348-352.
Subak L, Wing R, West, DS, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481-490.
Treatment of incontinence. Continence Foundation website. Available at: http://www.continence-foundation.org.uk. Accessed December 19, 2017.
Urinary incontinence. Urology Care Foundation website. Available at: http://www.urologyhealth.org/urologic-conditions/urinary-incontinence. Updated March 2013. Accessed December 19, 2017.
Urinary incontinence in men. EBSCO DynaMed Plus website. Available at:http://www.dynamed.com/topics/dmp~AN~T900624/Urinary-incontinence-in-men. Updated May 31, 2017. Accessed December 19, 2017.
Wein AJ, Rackley RR. Overactive bladder: a better understanding of pathophysiology, diagnosis, and management. J Urol. 2006;175(3 Pt 2):S5-S10.
12/3/2010 DynaMed's Systematic Literature Surveillancehttp://www.dynamed.com/topics/dmp~AN~T900624/Urinary-incontinence-in-men: Cardozo L, Khullar V, Wang JT, Guan Z, Sand PK. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? BJU Int. 2010;106(6):816-821.
7/28/2014 DynaMed's Systematic Literature Surveillancehttp://www.dynamed.com/topics/dmp~AN~T116944/Benign-prostatic-hyperplasia-BPH: Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65(5):981-990.